Raymond James Financial Services Advisors’s Filana Therapeutics FLNA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,066	Closed	-$227K	–	3486
2023 Q4	$227K	Sell	10,066 -4,399	-30%	-$92.9K	﹤0.01%	2923
2023 Q3	$241K	Buy	14,465 +4,108	+40%	+$81.4K	﹤0.01%	2804
2023 Q2	$254K	Sell	10,357 -889	-8%	-$21.4K	﹤0.01%	2775
2023 Q1	$271K	Buy	11,246 +2,060	+22%	+$57.1K	﹤0.01%	2711
2022 Q4	$271K	Buy	9,186 +917	+11%	+$33K	﹤0.01%	2660
2022 Q3	$346K	Sell	8,269 -1,011	-11%	-$27.3K	﹤0.01%	2491
2022 Q2	$261K	Sell	9,280 -2,665	-22%	-$67.3K	﹤0.01%	2689
2022 Q1	$444K	Buy	11,945 +3,680	+45%	+$156K	﹤0.01%	2454
2021 Q4	$361K	Buy	8,265 +2,534	+44%	+$133K	﹤0.01%	2583
2021 Q3	$356K	Buy	5,731 +1,855	+48%	+$155K	﹤0.01%	2579
2021 Q2	$331K	Buy	+3,876	New	+$208K	﹤0.01%	2653

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Raymond James Financial Services Advisors's FLNA Position: Q1 2024 in Review

Raymond James Financial Services Advisors sold out of Filana Therapeutics (FLNA) in Q1 2024, closing a stake of 10,066 shares — an estimated $227K sold.

Raymond James Financial Services Advisors first reported a position in FLNA in Q2 2021 and held it in 11 quarters. The position peaked at $444K in Q1 2022. 143 funds tracked by Wall St. Rank hold FLNA as of Q1 2024.

Raymond James Financial Services Advisors reported no remaining Filana Therapeutics position as of Q1 2024 after selling out during the quarter.
Raymond James Financial Services Advisors sold 10,066 Filana Therapeutics shares in Q1 2024, an estimated $227K.
Raymond James Financial Services Advisors first reported a position in Filana Therapeutics in Q2 2021 and held it in 11 quarters.
Raymond James Financial Services Advisors's Filana Therapeutics position peaked at $444K in Q1 2022.
143 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2024, filed 22 Apr 2024.